Technical analysis of Veracyte, Inc. (VCYT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Price Performance
| 1 month | +12.09% |
| 3 months | -15.06% |
| Year-to-date | +13.23% |
| 1 year | +32.27% |
| 3 years | +121.21% |
| 5 years | +8.61% |
52-Week Range
| 52-week High | $60.91 |
| 52-week Low | $29.46 |
| Avg Volume (90d) | 1.4M |
Technical Indicators
| SMA 50 | $44.77 |
| SMA 200 | $42.53 |
| Beta | 1.96 |
| 30-day Volatility (annualised) | 59.6% |
| Price vs SMA 50 | +6.5% |
| Price vs SMA 200 | +12.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-11 | $47.34 | |
| 2025-12 | $42.10 | -11.1% |
| 2026-01 | $38.08 | -9.5% |
| 2026-02 | $36.59 | -3.9% |
| 2026-03 | $32.21 | -12.0% |
| 2026-04 | $32.92 | +2.2% |
| 2026-05 | $46.34 | +40.8% |
| 2026-06 | $58.73 | +26.7% |
| 2026-07 | $46.32 | -21.1% |
| 2026-08 | $43.19 | -6.8% |
| 2026-09 | $46.04 | +6.6% |
| 2026-10 | $47.67 | +3.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-03 | $0.43 | $147M |
| 2026-07-30 | $0.41 | $145M |
| 2026-05-05 | $0.34 | $130M |
| 2026-02-25 | $0.41 | $136M |
| 2025-11-04 | $0.32 | $125M |
| 2025-08-06 | $0.31 | $121M |
| 2025-05-07 | $0.12 | $111M |
Price
| Price | $47.67 |
| Market Cap | $3.8B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 32.72 |
| Price / Book | 2.63 |
| EV / EBITDA | 26.17 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 9.16 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 21.11 |